Home > News > 65/A comparison of hybrid AF ablation and cryoballoon ablation in a predominantly persistent AF population – A propensity score matched analysis
Arrhythmia
Read Time: < 1 min

65/A comparison of hybrid AF ablation and cryoballoon ablation in a predominantly persistent AF population – A propensity score matched analysis

Published Online: October 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr65
Authors: L Leung (Presenting Author) – St. George’s Hospital NHS Foundation Trust, London, UK; B Evranos – St. George’s Hospital NHS Foundation Trust, London, UK; H Gonna – St. George’s Hospital NHS Foundation Trust, London, UK; I Harding – St. George’s Hospital NHS Foundation Trust, London, UK; A Grimster – St. George’s Hospital NHS Foundation Trust, London, UK; A Li – St. George’s Hospital NHS Foundation Trust, London, UK; M Saba – St. George’s Hospital NHS Foundation Trust, London, UK; M Sohal – St. George’s Hospital NHS Foundation Trust, London, UK; MM Gallagher – St. George’s Hospital NHS Foundation Trust, London, UK
Quick Links:
Article
Article Information
Article:

Background: The objective of this single-centre study was to compare the long-term efficacy and safety outcomes of the hybrid AF ablation approach with cryoballoon ablation procedure for the treatment of atrial fibrillation. In the absence of randomised clinical trials, we conducted a propensity-score-matched comparison of those that had AF ablation via the hybrid approach and cryoballoon ablation only.

Methods: In this study, thirty-five patients had AF ablation via the hybrid approach, with at least a 6-month follow up duration after the endocardial ablation procedure. An equal number of 35 patients who had cryoballoon ablation for AF were propensity score matched in a 1:1 ratio. The epicardial and endocardial ablation procedures were performed sequentially in a staged manner, in keeping with local protocol.

Results: Seventy patients (age 70 ± 8 years, ejection fraction 0.55 ± 0.09, left atrial size 45 ± 6 mm, median body mass index of 32) with paroxysmal and persistent AF were analysed. Fifty-eight (83%) of the patients had persistent AF. After a median follow-up of 28 (9–36) months, 18 (51.4%) of the hybrid group and 14 (40%) of the cryoballoon group were free from arrhythmia without antiarrhythmic medication (p=0.23). There were no major complications except one inferior vena cava rupture in the hybrid group, which was treated successfully.

Conclusions: Long term outcomes for the hybrid AF ablation approach are promising and demonstrate the ability to maintain sinus rhythm in predominantly obese patients with a significantly dilated left atrium.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72